Research Summary For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown median progression-free survival (PFS) of less than six months and median overall survival (OS) of approximately one year. Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen
Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting, but accessibility to outpatient administration is expanding. Benefits of outpatient CAR-T administration include broader treatment access, cost savings, reduced healthcare burden, and potentially improved patient
Research Summary This study1 evaluated the Medicare cost impact of choosing among covalent Bruton tyrosine kinase inhibitors (cBTKis) for treatment-naïve (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). The analysis focused on differences in drug acquisition and management of grade
Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor receptor (EGFR)–mutated, Stage II to IIIB non-small cell lung cancer (NSCLC) were assigned 1:1:1 to receive neoadjuvant osimertinib (80mg orally once daily for at least
Research Summary Advances in T-cell redirecting therapy (TCRT), which includes chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engagers (TCEs), have favorably altered the treatment landscape of multiple myeloma (MM). Previous recommendations on TCRT use in relapsed/refractory MM (RRMM)
Research Summary Ciltacabtagene autoleucel (cilta-cel) is a second-generation autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) on the surface of plasma cells. It is approved for patients with relapsed/refractory multiple myeloma (RRMM) with at least
The phosphoinositide 3-kinase (PI3K)-AKT signaling pathway is a key regulator of cell growth, survival, and metabolism and is frequently altered in estrogen receptor–positive (ER+) breast cancer. Approximately 30 to 40 percent of advanced ER+ breast cancers have gain of function
Research Summary Bruton tyrosine kinase (BTK) inhibitors have improved the treatment landscape of chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation, highly selective, covalent BTK inhibitor that has demonstrated a high overall response rate (ORR) in relapsed/refractory CLL, including among
Research Summary Concurrent chemoradiotherapy (cCRT) followed by adjuvant durvalumab is the standard first-line treatment for patients with unresectable Stage III non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) expression of one percent or higher. Although KRAS mutations are
Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is an effective treatment option for relapsed/refractory multiple myeloma (RRMM). Nurses play a crucial role in the CAR-T therapy process, not only during, but also by providing patient care before and after
Research Summary For patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), EGFR-tyrosine kinase inhibitors (TKIs) can be used as first-line treatment. However, treatment resistance often occurs with first- or second-generation EGFR-TKI treatment, with T790M mutation being
Treatment with a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, such as abemaciclib, plus (+) endocrine therapy (ET) has been shown to improve survival in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer, compared
In preinvasive and invasive breast cancer, breast-conserving surgery (BCS) has demonstrated similar survival outcomes to mastectomy, in addition to improvements in outcomes such as health-related quality of life and patient satisfaction. Chest wall perforator flap (CWPF) reconstruction can be utilized
Research Summary Patients with chronic lymphocytic leukemia (CLL) and higher-risk genomic features, such as unmutated immunoglobulin heavy chain variable (IGHV), del(17p) and/or TP53 mutations, and complex karyotype (CK), traditionally have a poorer prognosis, compared to patients without such features. Acalabrutinib,
Research Summary Up to 35 percent of patients with completely resected non-small cell lung cancer (NSCLC) experience locoregional recurrence (LR), and many of these patients cannot undergo further surgery. Other treatment methods are thus necessary for this patient population. Patients
Preoperative window-of-opportunity studies can provide key information on molecular drug response, pharmacodynamic (PD) effects, and downstream effects of medications, such as endocrine therapy (ET), in early breast cancer, as well as potentially predicting impact in advanced breast cancer. Data from
Endocrine therapy (ET) is the standard of care for patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC), but efficacy and patient experiences can be improved upon. Preclinical data has shown that the next-generation oral selective estrogen receptor degrader (SERD)
Research Summary Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations have a notably increased incidence of brain metastases, compared to patients without EGFR mutations. Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, has demonstrated intracranial activity,
Research Summary Bruton tyrosine kinase (BTK) inhibitors are often used to treat chronic lymphocytic leukemia (CLL). Ibrutinib is a covalent BTK inhibitor associated with adverse events (AEs), including cardiovascular toxicities; the incidence of AEs might be in part due to
Research Summary Acalabrutinib, a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy and tolerability in the treatment of chronic lymphocytic leukemia (CLL). In the Phase III, randomized, multicenter, open-label ASCEND trial, acalabrutinib was compared to investigator’s choice of
©2025 Oncology Matrix. All Rights Reserved.
